$21.84+0.14 (+0.65%)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACADIA Pharmaceuticals Inc. in the Healthcare sector is trading at $21.84 with a market capitalization of $3.7B. Wall Street consensus targets $31.65 (20 analysts), implying a +44.9% move over the next 12 months. The stock is currently 23% below its 52-week high of $28.35, remaining 6.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agon...
Recent performance snapshot ACADIA Pharmaceuticals (ACAD) has drawn investor attention following recent share performance, with the stock closing at US$21.56 and recording declines over the past week, month and past three months. See our latest analysis for ACADIA Pharmaceuticals. Recent share price momentum for ACADIA Pharmaceuticals has been fading, with the stock down over the past month and year to date, while the 1 year and 5 year total shareholder returns also show declines. If ACADIA's...
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo